Skip to content
Sunday, November 15, 2026
SmartLabel ITE Blog

Giving Stem Cells During Pregnancy to Babies with Spina Bifida Boosts Life Outcomes, Trial Finds

An innovative research effort has revealed that administering stem cells to fetuses affected by spina bifida during corrective surgery may represent a "major milestone" in treating birth defects.

Study Parameters and Security

The research conducted in the United States examined six fetuses with the 'open' form of spina bifida. Surgeons applied placenta-derived mesenchymal stem cells directly onto the developing neural column as part of the surgical correction.

Significantly, the cell therapy proved to be secure. Researchers confirmed that the therapy did not induce neoplasms, disrupt the healing process, or impede the resolution of co-occurring hindbrain herniation.

Promising Outcomes

Post-birth MRI scans showed a complete reversal of brainstem displacement in each of the babies. This neurological improvement is closely linked to improved motor skills and quality of life.

"If it makes a greater number of infants capable of walking who otherwise would not, it could establish itself as the new treatment paradigm," commented the principal investigator. "These findings are extremely promising and open the door to numerous possible innovative interventions."

Broader Impact and Encouragement

Independent medical specialists proposed that additional validation of these observed advantages could announce a "fresh chapter" in in-utero treatment. The potential to improve neural deficits seen in utero is viewed as a paradigm-shifting aim.

Notably important would be better management of bladder and bowel function, which are common challenges for people affected by this disorder.

The Path Forward

Despite this being a first-in-human effort involved a limited number of patients, its safety demonstration and positive signals create a solid basis for expanded clinical research. The integration of stem cell therapy with established fetal surgery techniques offers substantial hope for improving the prognosis for babies yet to be born with myelomeningocele.

About the author

Destiny Kelley

Lena is een IT-specialist met een passie voor het schrijven over opkomende technologieën en hun impact op het bedrijfsleven.

SmartLabel ITE Blog

Type to search articles.